Immune cell combo shows promise for tough childhood cancers

NCT ID NCT05400603

Recruiting now Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether giving children with advanced neuroblastoma or osteosarcoma a special type of immune cell (gamma delta T cells) from a healthy donor, along with several standard cancer drugs, is safe and tolerable. The study will enroll 24 children aged 1 and older whose cancer has not responded to or has returned after previous treatments. The main goal is to find the best dose of the immune cells to use in future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gamma delta T cells (immune cells from a healthy donor) plus dinutuximab, temozolomide, irinotecan, and zoledronate
What this could lead to: If it works, this could offer a new treatment option for children with neuroblastoma or osteosarcoma that has not responded to standard therapy.
What could go wrong: This is a very early, small phase 1 trial focused on finding a safe dose, not on proving effectiveness. The combination therapy may cause serious side effects, and the immune cells might not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroblastoma osteosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROBLASTOMA REFRACTORY NEUROBLASTOMA REFRACTORY OSTEOSARCOMA RELAPSED NEUROBLASTOMA RELAPSED OSTEOSARCOMA

Contacts and locations

Locations

Children's Healthcare of Atlanta
RECRUITING

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.